Restricted accessResearch articleFirst published online 2006-9
Multiple-target Chemotherapy (Lv-modulated 5-FU Bolus and Continuous Infusion,Oxaliplatin,CPT-11) in Advanced 5-Fu-refractory Colorectal Cancer: Mtd Definition and Efficacy Evaluation. A Phase I-II Study
To identify the maximum tolerated doses and to define the activity of a regimen incorporating leucovorin (LV)-modulated 5-fluorouracil (5-FU) bolus and continuous infusion, oxaliplatin (I-OHP) and irinotecan (CPT-11) in patients with advanced, 5-FU-refractory colorectal cancer (CRC).
Patients and Methods
Starting doses: LV 100 mg/m2 as a 2-hour infusion followed by 5-FU 300 mg/m2 bolus administration followed by 5-FU 500 mg/m2 as a 22-hour infusion on days 1 and 2; I-OHP 65 mg/m2 as a 2-hour infusion concomitantly with LV on day 1; CPT-11 90 mg/m2 concomitantly with LV on day 2. Planned cycle interval: 2 weeks.
Results
Two hundred twenty-six cycles were administered to 27 patients. Recommended doses were 5-FU bolus 300 mg/m2, 5-FU protracted infusion 500 mg/m2, l-OHP 75 mg/m2, and CPT-11 150 mg/m2. Among 25 patients evaluable for response we observed 13 disease stabilizations (52%; 95% CI: 33-71%), 6 instances of disease progression and 6 responses (24%; 95% CI: 7-41%). Median time to progression and overall survival were 24 and 60 weeks, respectively. A cycle delay >3 days was observed in 134/199 cycles (67%).
Conclusions
This study confirms the feasibility of triplet chemotherapy in patients with advanced 5-FU-refractory CRC.
KellyH., GoldbergR.M.: Systemic therapy for metastatic colorectal cancer: current options, current evidence.J Clin Oncol,23: 4553–4560, 2005.
2.
SobreroA.F., AscheleC., BertinoJ.R.: Fluorouracil in colorectal cancer - A tale of two drugs: implications for biochemical modulation.J Clin Oncol,15: 368–381, 1997.
3.
De GramontA., KrulikM., CadyJ., LagadecB., MaisaniJ.E., LoiseauJ.P., GrangeJ.D., Gonzalez-CanaliG., DemuynckB., LouvetC.: High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.Eur J Cancer Clin Oncol,24: 1499–1503, 1988.
4.
De GramontA., BossetJ.F., MilanC., RougierP., BoucheO., EtienneP.L., MorvanF., LouvetC., GuillotT., FrancoisE., Be-denneL.: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.J Clin Oncol,15: 808–815, 1997.
5.
RixeO., OrtuzarW., AlvarezM., ParkerR., ReedE., PaullK., FojoT.: Oxaliplatin, tetraplatin, cisplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel.Biochem Pharmacol,52: 1855–1865, 1996.
6.
GrotheyA., GoldbergR.M.: A review of oxaliplatin and its clinical use in colorectal cancer.Expert Opin Pharmacother,5: 2159–2170, 2004.
7.
RaymondE., Buquet-FagotC., DiellgulS., MesterJ., CvitkovicE., AllainP., LouvetC., GespachC.: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.Anticancer Drugs,8: 876–885, 1997.
8.
BonettiA., ZaninelliM., LeoneR., FranceschiT., FracconA.P., PasiniF., SabbioniR., CettoG.L., SichD., BrienzaS., HowellS.B.: Use of the ratio of time to progression following first-and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma.Ann Oncol,12: 187–191, 2001.
9.
BrienzaS., BensmaïneM.A., SoulièP., LouvetC., GamelinE., FrancoisE., DucreuxM., MartyM., AndreT., de BraudF., BleibergH., SegalF., ItzhakiM., CvitkovicE.: Oxaliplatin added to 5-fluorouracil-based therapy (5-FU ± FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.Ann Oncol,10: 1311–1316, 1999.
10.
AndréT., BensmaineM.A., LouvetC., FrancoisE., LucasV., DesseigneF., BeerblockK., BoucheO., CarolaE., MerroucheY., MorvanF., Dupont-AndréG., de GramontA.: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.J Clin Oncol,17: 3560–3568, 1999.
11.
AndreT., LouvetC., RaymondE., TurnigandC., de GramontA.: Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.Ann Oncol,9: 1251–1253, 1998.
12.
RothenbergM.L., OzaM., BigelowR.H., BerlinJ.D., MarshallJ.L., RamanathanR.K., HartL.L., GuptaS., GarayC.A., BurgerB.G., Le BailN., HallerD.G.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III study.J Clin Oncol,21: 2059–2069, 2003.
13.
VanhoferU., HarstrickA., AchterrathW., CaoS., SeeberS., RustumY.M.: Irinotecan in the treatment of colorectal cancer: clinical overview.J Clin Oncol,19: 1501–1518, 2001.
14.
SinhaB.K.: Topoisomerase inhibitors. A review of their therapeutic potential in cancer.Drugs,49: 11–19, 1995.
15.
TanizawaA., FujimoriA., FujimoriY., PommierY.: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivative presently in clinical trials.J Natl Cancer Inst,86: 836–842, 1994.
16.
Zeghari-SqualliN., RaymondE., CvitkovicE., GolwasserF.: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.Clin Cancer Res,5: 1189–1196, 1999.
17.
WassermanE., CuvierC., LokiecF., GoldwasserF., KallaS., Mery-MignardD., OuldkaciM., BensmaineA., Dupont-AndreG., MahjoubiM., MartyM., MissetJ.L., CvitkovicE.: Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.J Clin Oncol,17: 1751–1759, 1999.
18.
GoldwasserF., Gross-GoupilM., TigaudJ.M., Di PalmaM., Marceau-SuissaJ., WassermanE., YovineA., MissetJ.L., CvitkovicE.: Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.Ann Oncol,11: 1463–1470, 2000.
19.
SaltzL.B., CoxJ.V., BlankeC., RosenL.S., FehrenbacherL., MooreM.J., MarounJ.A., AcklandS.P., LockerP.K., PirottaN, ElfringG.L., MillerL.L.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.N Engl J Med,343: 905–914, 2000.
20.
DouillardJ.Y., CunninghamD., RothA.D., NavarroM., JamesR.D., KarasekP., JandikP., IvesonT., CarmichaelJ., AlaklM., GruiaG., AwadL., RougierP.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomised trial.Lancet,355: 1041–1047, 2000.
21.
GoldbergR.M., SargentD.J., MortonR.F., FuchsC.S., RamanathanR.K., WilliamsonS.K., FindlayB.P., PitotH.C., AlbertsS.R.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.J Clin Oncol,22: 23–30, 2004.
22.
De GramontA., FigerA., SeymourM., HomerinM., HmissiA., CassidyJ., BoniC., Cortes-FunesH., CervantesA., FreyerG., PapamichaelD., Le BailN., LouvetC., HendlerD., de BraudF., WilsonC., MorvanF., BonettiA.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol,18: 2938–2947, 2000.
23.
GrotheyA., DeschlerB., KroeningH., RidwelskiK., Re-ichardtP., KretzschmarA., ClemensM., HirschmannW., LorenzM., AspergerW., BuecheleT., SchmollH.J.: Phase III study of bolus 5-fluorouracil (5FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin in advanced colorectal cancer.Proc ASCO,21: 129, 512(abstr), 2002.
24.
MillerA.B., HoogstratenB., StaquetM.: Reporting results of cancer treatment.Cancer,47: 207–214, 1981.
25.
HryniukW., BushH.: The importance of dose intensity of chemotherapy of metastatic breast cancer.J Clin Oncol,2: 1281–1288, 1984.
26.
ComellaP., CasarettiR., De RosaV., AvalloneA., RizzoF., FioreF., LapentaL., ComellaG.: Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.Ann Oncol,13: 1874–1881, 2002.
27.
CalvoE., CortesJ., Gonzalez-CaoM., RodriguezJ., AramendiaJ.M., Fernandez-HidalgoO., Martin-AlgarraS., SalganoJ.E., Martinez-MongeR., de IralaJ., BrugarolasA.: Combined irinotecan, oxaliplatin, and 5-fluorouracil in patients with advanced colorectal cancer: a feasibility pilot study.Oncology,63: 254–265, 2002.
28.
FalconeA., MasiG., AllegriniG., DanesiR., PfannerE., BrunettiI.M., Di PaoloA., CupiniS., Del TaccaM., ConteP.: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.J Clin Oncol,19: 4006–4014, 2002.
29.
CalsL., RixeO., FrancoisE., FavreF., MeradL., DeplanqueG., LaademA., JuinP., BerederJ.M., BernardiniD., HeraitP.: Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer.Ann Oncol,15: 1018–1024, 2004.
30.
SouglakosJ., MavroudisD., KakolyrisS., KourousisCh, Var-dakisN., AndroulakisN., AgelakiS., KalbakisK., TsetisD., AthanasiadisN., SamonisG., GeorgouliasV.: Triplet combination with irinotecan plus oxaliplatin plus continuous infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.J Clin Oncol,20: 2651–2657, 2002.
31.
MasiG., AllegriniG., CupiniS., MarcucciL., CerriE., BrunettiI., FontanaE., RicciS., AndreuccettiM., FalconeA.: First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.Ann Oncol,15: 1766–1772, 2004.
32.
CalvoE., CortesJ., RodriguezJ., Fernandez-HidalgoO., RebolloJ., Martin-AlgarraS., Garcia-FoncillasJ., Martinez-MongeR., de IralaJ., BrugarolasA.: Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.Clin Colorectal Cancer,2: 104–110, 2002.
33.
YchouM., ConroyT., SeitzJ.F., GourgouS., HuaA., Mery-MignardD., KramarA.: An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors.Ann Oncol,14: 481–489, 2003.
34.
GoetzM.P., ErlichmanC., WindebankA.J., ReidJ.M., SloanS.M., AthertonP., AdjeiA.A., RubinJ., PitotH., GalanisE., AmesM.M., GoldbergR.M.: Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors.J Clin Oncol,20: 3761–3769, 2003.
35.
SeiumY., StuppR., RuhstallerT., GervazP., MenthaG., PhilippeM., AllalA., TrembleauC., BauerJ., MorantR., RothA.D.: Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.Ann Oncol,16: 762–766, 2005.
36.
FalconeA., MasiG., MurrR., BenedettiG., BertettoO., Fer-raldeschiR., ChiaraS., GranettoC., AlabisioO., RicciS.: Biweekly irinotecan, oxaliplatin and infusional 5FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (GONO).Proc ASCO GI, 199, 227(abstr), 2006.
FischelJ.L., RostagnoP., FormentoP., DubreuilA., EtienneM.C., MilanoG.: Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.Br J Cancer,84: 579–585, 2001.
39.
GrotheyA., SargentD.: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.J Clin Oncol,23: 9441–9442, 2005.
40.
SeymourT., for the UK NCRI Colorectal Clinical Studies Group: Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer (ACRC).Proc ASCO, 24: 250s, 3518(abstr), 2005.
